Elgin, IL , USA, 28-Mar-2018 — /EuropaWire/ — Royal DSM, a global science-based company active in health, nutrition and materials, announces its commitment to bring innovative solutions to the biofuels industry with a full portfolio offering of yeast and enzymes for starch, fiber and biomass conversions.
Innovation is at the core of DSM’s business with over one hundred years of experience in research, development and production of biotechnology. DSM continues to invest in the biofuel industry and has a dedicated team working on the development and commercialization of products and services for the industry. Global research facilities exist for the business in Illinois, USA and in Delft, the Netherlands.
DSM offers a range of yeast and enzyme solutions that enhance performance based on proprietary technology.
Our yeast and enzymes are manufactured in the USA. In addition, DSM offers a unique opportunity for on-site manufacturing of enzymes and the first of its kind facility is currently under construction at POET-DSM.
“We are excited about the growth that is taking place in the biofuels industry and the opportunity to offer a variety of different solutions that will enhance production capabilities” says Atul Thakrar, President of DSM Bio-based Products and Services. “DSM is committed to the journey of advancing the industry and looks forward to continuing to work with the market to create valuable solutions that enhance starch, fiber and biomass processes. Product announcements on our solutions will be issued shortly.”
SOURCE: DSM
Contact
For more Information:
DSM Bio-based Products & Services
Kelly Hawkinson, Marketing & Sales Director
+1 847 214 3845
kelly.hawkinson@dsm.com >
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…